Please provide your email address to receive an email when new articles are posted on . Single maintenance and reliever therapy (SMART) had a lower total annual asthma management cost vs. traditional ...
Experts say no inhaler suits every patient with chronic obstructive pulmonary disease, and technique can fade within 30 days without retraining.
A narrative review synthesizes real-world evidence supporting single-inhaler triple therapy and the emergence of dupilumab, ...
Please provide your email address to receive an email when new articles are posted on . Compared with a dual therapy inhaler, a triple therapy inhaler improved inspiratory capacity in those with COPD.
Inhalers In patients with COPD, treatment with single-inhaler fluticasone furoate/umeclidinium/vilanterol resulted in more health status improvements and greater lung ...
MADRID — For patients whose asthma is not well controlled, the addition of a long-acting muscarinic antagonist to the two-drug combination of an inhaled corticosteroid and a long-acting beta2 agonist ...
Inhalers Single-inhaler triple therapy is associated with a favorable benefit-risk profile compared with dual therapy for patients with symptomatic COPD and a history of exacerbations. Single-inhaler ...
A preliminary study of 52,330 Israeli women found similar rates of heart attack, stroke, blood clots and early death among hormone therapy users and nonusers, though it cannot prove safety. Older ...
IMPACT and ETHOS reported fewer deaths with triple therapy, yet neither Trelegy nor Breztri carries that claim, and critics blame ICS withdrawal. Both now treat asthma too.
Patients with severe asthma which is not controlled with standard treatment -- leaving them at risk of severe asthma attacks -- could benefit from using a single inhaler combining three, instead of 2 ...
RICHMOND, Va., Jan. 7, 2025 /PRNewswire/ -- Qnovia, Inc., a pharmaceutical company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery ...
This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2004, asreported in ONI. Guest editor Dr. Roy ...